Summer’s venture wave; drugging beta-catenin; Capricor & FDA  

• Venture financings — Nearly $800 million in new biotech venture capital suggests investors remain open to well-positioned private companies with credible differentiation and high-value clinical or platform narratives. Biotechs raising money last week included Deerfield-incubated Boulevard Bio, Foresite Capital-backed Khartis, and Swiss biotech Vaderis

• β-catenin in cancer — New approaches to an undruggable pathway point to fresh competitive opportunities in oncology, but success will depend on translating difficult biology into workable product strategies...